In vitro effect of Cetuximab on conjunctival squamous cell carcinoma
Parya Abdolalizadeh1 *, Hossein Aghaei2 , Yasaman Hadi2
- Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
- Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
Abstract: To assess the effect of various doses of cetuximab on conjunctival squamous cell carcinoma (SCC).
Methods: This is an in-vitro interventional comparative study. Fifteen conjunctival specimens of one patient with conjunctival SCC were exposed to various doses (0, 100, 200, 500, and 1000 µm/ml) of cetuximab. The cell numbers of SCC were counted at time intervals of 24, 48, 72, and 120 hours.
Results: There are five groups including cetuximab-exposed groups with doses 100, 200, 500, and 1000 µm/ml and one control group. For each group, three specimens were allocated. In all groups except control group, the cell counts of SCC decreased. In 500 and 1000 µm/ml cetuximab groups, all SCC cells were died after 72 hours.
Conclusion: Cetuximab can be considered as a topical therapy for patients with conjunctival SCC.
